Cellenkos Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
M&A
- (Cancelled)
- Investors
-
3
Cellenkos General Information
Description
Developer of tissue-directed regulatory T cell therapies designed for autoimmune and neurodegenerative diseases. The company's technology utilizes a proprietary platform to engineer cord blood-derived cells with specific homing markers, providing patients with off-the-shelf infusions that traffic directly to inflamed tissues to restore immune homeostasis.
Contact Information
Website
www.cellenkosinc.comCorporate Office
- 5416 Chaucer Drive
- Houston, TX 77005
- United States
Corporate Office
- 5416 Chaucer Drive
- Houston, TX 77005
- United States
Cellenkos Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 29-Apr-2022 | Cancelled | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series A) | 04-Nov-2021 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC | 20-Sep-2016 | $10M | $10M | Completed | Pre-Clinical Trials | |
| 1. Joint Venture | 18-Sep-2016 | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Cellenkos Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Cellenkos Patents
Cellenkos Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025239644-A1 | Uses of regulatory t cells for treating amyotrophic lateral sclerosis | Pending | 19-Mar-2024 | ||
| WO-2025199206-A1 | Uses of regulatory t cells for treating amyotrophic lateral sclerosis | Pending | 19-Mar-2024 | ||
| AU-2024369426-A1 | Uses of regulatory t cells for treating myelofibrosis | Pending | 31-Oct-2023 | ||
| EP-4828021-A1 | Uses of regulatory t cells for treating myelofibrosis | Pending | 31-Oct-2023 | ||
| WO-2025094066-A1 | Uses of regulatory t cells for treating myelofibrosis | Inactive | 31-Oct-2023 | A61P35/00 |
Cellenkos Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cellenkos Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BVCF | Venture Capital | Minority | ||
| Golden Meditech | Corporation | Majority | ||
| UT MD Anderson | Corporation | Majority |
Cellenkos FAQs
-
When was Cellenkos founded?
Cellenkos was founded in 2016.
-
Where is Cellenkos headquartered?
Cellenkos is headquartered in Houston, TX.
-
What is the size of Cellenkos?
Cellenkos has 11 total employees.
-
What industry is Cellenkos in?
Cellenkos’s primary industry is Drug Discovery.
-
Is Cellenkos a private or public company?
Cellenkos is a Private company.
-
What is Cellenkos’s current revenue?
The current revenue for Cellenkos is .
-
How much funding has Cellenkos raised over time?
Cellenkos has raised $25M.
-
Who are Cellenkos’s investors?
BVCF, Golden Meditech, and UT MD Anderson have invested in Cellenkos.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
